|
Pluristem Files Patent Application For PLX-1, Intended as an
Innovative Stem Cell Solution For Improved Engraftment During Bone Marrow
Transplantation
Monday May 8, 8:30 am ET |
|
HAIFA, Israel--(BUSINESS WIRE)--May 8, 2006--Pluristem Life Systems,
Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the
commercialization of stem cell products, today announced that a patent
application has been filed with the US Patent and Trademark Office for
its stem cell therapy product known as PLX-1. PLX-1 is intended to offer
a breakthrough solution to improved engraftment during bone marrow
transplant procedures that use umbilical cord blood (UCB).
PLX-1, which consists of propagated (adjuvant engineered) mesenchymal
stem cells (MSC) that can be co-transplanted along with the
hematopoietic stem cells (HSC), is expected to significantly improve the
engraftment rate of the HSCs.
The role of PLX-1 is to improve the homing of hematopoietic stem cells
and their lodgment into the patient hematopoietic niche using engineered
mesenchymal cells. This new technology is based on using Pluristem's ex
vivo expanded Engineered Mesenchymal Cells (EMC) that are expanded
within the proprietary PluriX(TM) high density 3-D cultures system.
The EMC cells are expanded to achieve the quality and amount required
for improving HSC and progenitor cell repopulation, and to enhance bone
marrow engraftment following stem cell transplantation.
Mr. Zami Aberman, CEO, stated, "PLX-1 represents the broadening of
Pluristem's previously granted patents and pending patents that have
already revolutionized HSC expansion through the use of Pluristem's
unique 'human-like' bone marrow micro-environment. Until now the field
of bone marrow transplantation has been limited to procedures and
technologies that expand hematopoietic stem cells only. PLX-1's novel
approach creates a new playing field in which cells of mesenchymal
origin play a central role. As such, PLX-BMT could become a mandatory
adjuvant therapy to any methodology used in bone marrow transplants,
either through standard clinical transplantation of cord blood or
through the use of manipulated HSCs. This opens the door for Pluristem
to reach an annual market of approximately 100,000 clinical procedures."
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements". Those statements include statements
regarding the intent, belief or current expectations of Pluristem Life
Systems, Inc., and members of our management as well as the assumptions
on which such statements are based. Forward-looking statements in this
release include that PLX-1 is intended to offer a breakthrough solution
to improved engraftment during bone marrow transplants; that PLX-1 is
expected to significantly improve the engraftment rate of HSCs; that its
role is to improve the homing of hematopoietic stem cells and their
lodgment into the patient; that PLX-1's novel approach creates a new
playing field in which cells of mesenchymal origin play a central role;
that PLX-BMT could become a mandatory adjuvant therapy to any methodology
used in bone marrow transplants; and that this opens the door for
Pluristem to reach an annual market of approximately 100,000 clinical
procedures. Actual outcomes and our actual results could differ
materially from those in such forward-looking statements, as we may find
that our processes do not work as well in practice as in theory; we may
encounter side effects or other adverse consequences of using our
technology; our current patents may be attacked and defeated in patent
proceedings; our patent filings may be rejected by the patent offices;
other companies may discover and develop better or cheaper technologies
that would render our processes obsolete; and we may not have sufficient
funding to develop our technology. As well, our products may never
develop into useful products and even if they do, they may not be
approved for sale to the public. For further risk factors see the
Company's latest 10-KSB filed with the SEC.
|
|
Contact:
Pluristem Life Systems, Inc.
Yossi Keret, ++972-54-800-8404
Yossi@pluristem.com
Source: Pluristem Life Systems, Inc. |
|
